Investors have had an appetite for cannabis stocks since recreational marijuana was legalized in Canada last year. Wall Street analysts are now taking notice, and Stifel is the latest firm to weigh in on Cronos Group Inc CRON.
The Analyst
On Thursday, Stifel analyst W. Andrew Carter initiated coverage of Cronos with a Hold rating and C$18 ($13.44 USD) price target.
Need more cannabis news? Check out all of our coverage here.
The Thesis
Carter said Cronos is well-positioned for the booming Canadian adult-use marijuana market and has the resources, capital and partnerships to potentially attack the global market in the long-term. Carter is especially optimistic about Cronos’ partnership with tobacco giant Altria Group Inc MO, which invested about $2 billion to help with the Cronos growth push.
With the stock up 125 percent in the past year, Carter said the market has gotten a bit ahead of itself.
“Our near-term target price for the shares suggests some downside potential given the unbridled enthusiasm that has taken hold here following the investment by Altria pushing the valuation to the top of the industry,” Carey wrote in a note.
For now, Carey said investors should remain patient and look to buy shares on any major pullback opportunities.
Carey says Cronos is also focused on delivering the same type of innovation with its cannabis vapor products that Apple, Inc. AAPL brought to the smartphone industry when it launched the iPhone. Altria’s tobacco expertise has helped Cronos prepare for having vaping products ready for launch on day one of legalization last October.
Price Action
Cronos shares traded about 1 percent lower to $15.86 on Thursday.
Related Links:
Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US
Stifel: Canopy Growth Is The 'Best Investable Opportunity' In Cannabis
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!